GEOFFREY B. DAVIS JOINS GT BIOPHARMA’S BOARD OF
DIRECTORS
LOS
ANGELES, CA, January 16, 2018 - GT Biopharma Inc. (OTCQB: GTBP and
Euronext Paris "GTBP.PA") today announced that Geoffrey B. Davis
will join GT Biopharma's Board of Directors effective immediately.
Mr. Davis is the founding partner of Barker Davis, a law firm
focused on Life Sciences transactions, and formerly a partner at
Ropes & Gray, where he played a significant role in
establishing the firm’s internationally recognized Life
Sciences group.
“As
a veteran life sciences attorney, Geoff’s experience will
complement the seasoned biotechnology management team that we added
over the last 6 months. His appointment represents another
milestone for GT Biopharma and significant accomplishment towards
our goal of creating a premier company in the biotech
community,” said Anthony J. Cataldo, Executive Chairman of GT
Biopharma.
"We are
extremely pleased to welcome Geoff to GT Biopharma’s Board of
Directors," said Dr. Kathleen
Clarence-Smith, Chief Executive Officer of GT Biopharma.
“We expect Geoff’s substantial experience and
expertise, particularly in the completion of business development
transactions, to be a significant asset to the company, as we
continue to execute on our strategy, focused on becoming a leading
biopharmaceutical company."
Mr.
Davis has extensive experience representing biotechnology,
biomedical, medical device and pharmaceutical companies. During his
more than 25 years as a partner at Ropes & Gray, Geoff played a
significant role in establishing the firm’s internationally
recognized Life Sciences group. His work includes numerous
corporate partnering and licensing transactions for major
pharmaceutical and medical device companies, as well as for public
and private biotechnology companies and major medical centers. He
has also worked extensively on public and private financings for
biomedical companies of all sizes, ranging from newly organized
companies to established industry leaders, on behalf of both
companies and their investment bankers.
Mr.
Davis received his B.A., cum
laude, from Yale University and his J.D., cum laude, from Harvard Law
School.
About GT Biopharma, Inc.
GT
Biopharma, Inc. is an immuno-oncology biotechnology company focused
on innovative treatments based on the company’s proprietary
Tri and Tetra-specific Natural Killer Cell Engagers (TriKEs™
and TetraKEs) and bispecific antibody-drug conjugate (ADC)
platforms. GT's most advanced oncology drug candidate, OXS-1550
(DT2219) is a novel bispecific scFv recombinant fusion protein-drug
conjugate composed of the variable regions of the heavy and light
chains of anti-CD19 and anti-CD22 antibodies and a modified form of
diphtheria toxin as its cytotoxic drug payload. OXS-1550 has
demonstrated success in early human clinical trials in patients
with relapsed/refractory B-cell lymphoma or leukemia. In addition,
GT's TriKE platform will address a number of cancer types. GT's
nervous system platform is focused on acquiring or discovering and
patenting late-stage, de-risked, and close-to-market improved
treatments for nervous system diseases (Neurology and Pain) and
shepherding them through the approval process to the NDA. GT
Biopharma's neurology products currently include PainBrake, as well
as treatments for the symptoms of myasthenia gravis, and motion
sickness.
Except
for historical information contained herein, the statements in this
release are forward-looking and made pursuant to the safe harbor
provisions of the Private Securities Litigation Reform Act of 1995.
Forward-looking statements are inherently unreliable and actual
results may differ materially. Examples of forward-looking
statements in this news release include statements regarding the
effectiveness of the Company's products, the potential outcome of
clinical studies, the future success of development activities and
the future growth and operating and financial performance of the
Company. Factors which could cause actual results to differ
materially from these forward-looking statements include such
factors as the Company's ability to accomplish its business
initiatives, obtain regulatory approval and protect its
intellectual property; significant fluctuations in marketing
expenses and ability to achieve or grow revenue, or recognize net
income, from the sale of its products and services, as well as the
introduction of competing products, or management's ability to
attract and maintain qualified personnel necessary for the
development and commercialization of its planned products, and
other information that may be detailed from time to time in the
Company's filings with the United States Securities and Exchange
Commission. The Company undertakes no obligation to publicly update
or revise any forward-looking statements, whether as a result of
new information, future events or otherwise.
Contact:
Westwicke
Partners
John
Woolford
(443)
213-0506
john.woolford@westwicke.com